{"disease":{"id":"diffuse-systemic-sclerosis","name":"diffuse systemic sclerosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07000916","title":"Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT03398837","title":"Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":365,"lead_sponsor_name":"Corbus Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04781543","title":"A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":301,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05168215","title":"Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT06470048","title":"A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05626751","title":"An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":174,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05270668","title":"Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154,"lead_sponsor_name":"Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT06925542","title":"A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"CRISPR Therapeutics","has_results":false},{"nct_id":"NCT04440592","title":"Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Tanabe Pharma America, Inc.","has_results":true},{"nct_id":"NCT07292961","title":"Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma","phase":"NA","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Hacettepe University","has_results":false},{"nct_id":"NCT06375005","title":"Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03919799","title":"KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Kadmon, a Sanofi Company","has_results":true},{"nct_id":"NCT04137224","title":"Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT03222492","title":"Brentuximab Vedotin for Systemic Sclerosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT05149768","title":"Open Label Extension Study of Brentuximab Vedotin in Early dcSSc","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":11,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03198689","title":"Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT04680975","title":"Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Kadmon, a Sanofi Company","has_results":true},{"nct_id":"NCT04837131","title":"A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Michael M. Pham","has_results":true},{"nct_id":"NCT04478994","title":"A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04138485","title":"Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CSL Behring","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}